Realgar/Indigo naturalis

Realgar/Indigo naturalis
Combination of
RealgarArsenic compound
Indigo naturalisTraditional Chinese medicine
Names
Other namesRIF oral arsenic formulation, Compound Huangdai
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
Defined daily dosenot established[1]
Legal
Legal status
  • US: Not FDA approved

Realgar/Indigo naturalis (RIF), also known as Compound Huangdai, is a medication used to treat acute promyelocytic leukemia.[2] Effectiveness appears similar to arsenic trioxide.[2] It is generally used together with all-trans-retinoic acid (ATRA).[2] It is taken by mouth.[3]

Side effects may include abdominal pain and rash.[2] It is made up of a combination of realgar (tetra-arsenic tetra-sulfide), Indigo naturalis, root of Salvia miltiorrhiza, and root of Pseudostellaria heterophylla.[2] It works by breaking down the cancer protein retinoic acid receptor alpha.[4]

Realgar-Indigo naturalis was developed in the 1980s and approved for medical use in China in 2009.[2][5] It is on the World Health Organization's List of Essential Medicines.[3] It is made in China and was originally a herbal remedy.[2] It is not very expensive.[2] It is not approved in either the United States or Europe as of 2019.[2]

Dosage

The defined daily dose is not established.[1]

References

  1. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020.
  2. 1 2 3 4 5 6 7 8 9 "Proposal for the inclusion of arsenic therapies in the WHO Model list of ESSENTIAL MEDICINES for the treatment of acute promyelocytic leukemia" (PDF). WHO. Archived (PDF) from the original on 14 May 2020. Retrieved 15 November 2019.
  3. 1 2 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ↑ "realgar-Indigo naturalis formulation". National Cancer Institute. 2 February 2011. Archived from the original on 10 July 2019. Retrieved 15 November 2019.
  5. ↑ Ghosh, Dilip; Smarta, R. B. (2016). Pharmaceuticals to Nutraceuticals: A Shift in Disease Prevention. CRC Press. p. PT41. ISBN 9781315354934. Archived from the original on 2020-05-14. Retrieved 2019-11-15.
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.